NVO News and Press, Novo Nordisk A/S From 07/09/24

2024-07-09 22:22:11 ET Summary VIGI has underperformed due to market-wide preference for US mega-cap stocks, but valuation and diversification may lead to mean reversion favoring VIGI. 2Q is expected to mark the first growth quarter for "Other" 493, a potential catalyst for change...

2024-07-09 13:29:22 ET Summary Federal Reserve Chairman Jay Powell testified before the Senate Banking Committee, emphasizing the need for more data to confirm progress towards the Fed's 2% inflation goal. Changes in capital requirements for US' largest banks could save them billi...

2024-07-09 11:20:00 ET Summary Fundsmith Equity Fund underperformed the MSCI World Index in 2023 but has outperformed it since inception with lower price volatility. Fundsmith Equity Fund was up by 9.3% in the first six months of the year, 3.4 percentage points less than what is p...

2024-07-08 19:11:55 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal Wall Street Lunch: Merger Monday In All Its Glory Novo Nordisk: Buy On Dips Eli Lilly to acquire Morphic for $57 a share in ca...

2024-07-08 14:36:33 ET Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 ...

2024-07-06 14:00:00 ET More on Eli Lilly, Novo Nordisk Novo Nordisk: Buy On Dips Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval 5 Reasons Eli Lilly Just Keeps Rising Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst N...

2024-07-06 08:31:00 ET Summary Amgen investors have outperformed the S&P 500 easily since my last Buy rating in late 2021. AMGN stock has benefited from the obesity drug euphoria as AMGN's MariTide enters Phase III studies. Novo Nordisk and Eli Lilly are GLP-1 leaders and ...

2024-07-05 15:04:46 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk’s Ozempic, Wegovy linked to eye diso...

2024-07-05 05:45:00 ET With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for other treatments, it's natural for investors to assume that Nov...

2024-07-05 01:42:52 ET Summary Amgen shares have outperformed IBB by over 40% in the past year, driven higher by a major surge post-earnings in May. With a current price-to-earnings multiple in the mid-teens, I assert that solid and consistent EPS growth ahead warrants a higher va...